Colored particles with blue background_ 3d rendering. Computer digital drawing.
Nanoparticles in excipients and their potential impact on patients and pharmaceuticals
Tuesday, November 8, 2022 - 10:00am to 12:00pm EST

Webinar Description 
Nanomaterial continues to be a hot topic among regulatory agencies globally. The recent ban on TiO2 (E171) as a food additive in Europe has highlighted the need to have a comprehensive understanding of the global regulatory environment related to the presence of nanoparticles in food additives and excipients. The use of TiO2 in pharmaceutical and cosmetic applications is under review in the EU. There has not been any specific safety concern which has been scientifically demonstrated for E171 and the current ban in food is based on the precautionary principle and some uncertainties related to genotoxicity.

In Europe similar concerns have been voiced for many other food additives which are also excipients.

The regulatory and safety implications for the inclusion of these materials (containing a nanoparticle fraction) in pharmaceutical products is not clear. If these materials were to be banned in pharmaceuticals, the implications to patients could be severe (potential loss of life-saving medicines).

This webinar will provide an overview of the current situation related to TiO2 and other identified excipients containing nanoparticle fractions. In addition, a discussion of current regulatory and industry activities and their potential impact will be summarized.

Learning/Awareness Objectives
Attendees will be provided with:
> Background, overview and definitions of excipients containing nanoparticle fractions
> Current regulatory activities in the EU and other countries which may impact the use of these materials in pharmaceutical products
> Understanding of the extent of materials potentially impacted
> Current situation as it relates to TiO2 and potential alternatives
> Potential impact for patients, regulators and the industry
> Industry activities to proactively address these issues

Who should attend?
> Pharmaceutical formulators and development scientists
> Excipient manufacturers
> Regulatory affairs and legal professionals
> Safety evaluation professionals
> Compendial affairs
> Quality affairs
David R. Schoneker
President/Owner of Black Diamond
Regulatory Consulting, LLC

David R. Schoneker is currently the President/Owner of Black Diamond Regulatory Consulting, LLC, a consulting firm specializing in providing regulatory and quality consulting for the pharmaceutical, dietary supplement, food and related industries. The firm provides expert advice for difficult problems and training on excipient and food additive regulatory, quality and supply chain concerns.
Dr. Christian Moreton
FinnBrit Consulting

Dr. Moreton has over thirty years’ experience in the pharmaceutical industry, mainly as a formulation scientist developing a variety of different dosage forms, but also in QA/QC and Technical Support in excipients and drug delivery. Most recently, he has been responsible for the development of clinical and commercial drug products and associated analytical methods, working with clients, licensing partners and contractors.
General Registration: $179

Discounted registration is available for:
> IPEC-Americas Members ($89)
> Government Employees ($60)
> Students / Faculty ($20)
Save When You Bring Your Team
Register your staff using the same email domain to take advantage of our "Buy 4 get 1 Free" offer. Contact us for more information.

  IPEC-Americas
571-814-3449